WEST CONSHOHOCKEN, Pa., April 23, 2014 /PRNewswire/ -- Liventa Bioscience, (formerly AFCell Medical), one of the leading innovators of allograft implants from human amniotic membrane in the United States, has received notice that MiMedx Group, Inc. (MDXG), filed a patent infringement lawsuit against it, its partner in the wound care market, Medline and Liventa's processing partner, Musculoskeletal Transplant Foundation, Inc. (MTF).
Robin R. Young, CEO of Liventa Bioscience, said, "In our view this suit is without merit and we are working with counsel to vigorously defend each specific claim. We believe this suit is an attempt to slow the increasing inroads of our amniotic tissue wound care coverings among major hospital networks in the United States. We are also confident that our tissue forms do not infringe any of the patents asserted by MiMedx."
About Liventa Bioscience
Liventa Bioscience is a privately held, commercial stage biotechnology company focused on bringing advanced biologics to market. Its innovative allograft tissue forms come from living donors and are available through independent distribution. Liventa is currently offering or is in the process of developing a number of advanced orthopedic biologics. These products include human collagen membrane sheets derived from placental tissues, flowable wound coverings, and innovative new soft tissue repair coverings and protective implants.
For more information on Liventa, visit www.liventabioscience.com.
SOURCE Liventa Bioscience